LEGN
Legend Biotech Sees Bright Future for Blockbuster CAR-T Therapy
Legend Biotech, a leader in cell therapy, has achieved significant milestones in its fourth quarter of 2024 performance. The company's CEO, Ying Huang, highlighted the impressive progress made in bringing its CAR-T therapy, CARVYKTI, to patients with multiple myeloma. In a recent conference call, Legend Biotech executives discussed